BARDA has awarded Tangen Biosciences the Second Option of a contract to develop a molecular diagnostic platform that can be used by the company to rapidly develop infectious disease tests.
Last week, BARDA also announced that Tangen was awarded a separate contract to develop a rapid SARS-CoV-2 test for detection of COVID-19 infection utilizing Tangen’s platform.
BARDA is the U.S. Department of Health and Human Services’ Biomedical Advanced Research and Development Authority.